Navigation Links
Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
Date:5/13/2010

SEATTLE, May 13 /PRNewswire-FirstCall/ -- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company, today announced that, based on successful preclinical studies, the Company has selected a clinical candidate for its MASP-2 antibody program and has initiated the cGMP manufacturing development process in preparation for clinical trials. Preclinical studies have shown that Omeros' proprietary, fully human, monoclonal MASP-2 antibodies shut down the lectin pathway of the complement system, which is part of the immune system. The lectin pathway is involved in multiple inflammatory disorders and, in independent studies, patients who are genetically deficient in the pathway have been shown to have better clinical outcomes. MASP-2 inhibition has also demonstrated efficacy across a wide range of preclinical disease models.

"MASP-2 is an exciting target and, with our recent licensing of Helion's intellectual property, we have now consolidated within Omeros the worldwide exclusive rights to MASP-2 inhibition and the antibodies that target the protein," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "The preclinical data support our lead antibody's potential for broad utility in both orphan and major-market diseases. In addition, the clinical utility and commercial value of complement inhibition has been validated by the first and, currently, the only complement antibody on the market."

About Omeros' Program to Inhibit MASP-2 with Fully Human Antibodies

MASP-2 (mannan-binding lectin-associated serine protease-2) is a novel pro-inflammatory protein target in the complement system. Omeros has generated
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015  Delays in ... projects can slow down the decision-making process, resulting ... therefore, absolutely critical for biopharmaceutical companies to develop ... approval process for quicker and more meaningful insights. ... Best Practices, LLC, nearly three-quarters of benchmarked study ...
(Date:8/28/2015)... 2015 Research and ... of the "12th Annual Report and Survey ... to their offering. The 2015 12th ... and Production is the most recent study of ... projected future capacity and production. The report contains ...
(Date:8/28/2015)... 28, 2015 Research ... of the "Investigation Report on China,s Insulin ... Developed by Novo Nordisk, insulin aspart ... important drug for the treatment of diabetes. Compared ... acting insulin analog, starts working fast and reports ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2
... issued today a shareholders, letter discussing the results of its fiscal ... Dear Imagenetix shareholder - Following ... we commence the new fiscal year, I would like to address ...   Over the past few years our primary strategy ...
... July 12, 2011 Arena Pharmaceuticals, Inc. (NASDAQ: ... 1 clinical trial of APD811, an orally bioavailable agonist ... treatment of pulmonary arterial hypertension, or PAH. ... tolerability and pharmacokinetics of 0.03 mg, 0.05 mg, 0.1 ...
Cached Medicine Technology:Imagenetix, Inc. Discusses March 31, 2011 Fiscal Year End Results and Future Focus 2Imagenetix, Inc. Discusses March 31, 2011 Fiscal Year End Results and Future Focus 3Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension 4
(Date:8/29/2015)... ... 29, 2015 , ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, the Director ... Foundation) will present an educational program titled “Asbestos and Your Health.” , The two ... (doors open at 6:45pm) at Calvary United Methodist Church, 16 E Park Ave., Ambler, ...
(Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik , Eau Thermale Avene ... , “Before, a threshold of $49.00 was required to qualify for free standard shipping,” ... free standard shipping for customers regardless of the item’s selling price.” , With competitive ...
(Date:8/29/2015)... ... August 29, 2015 , ... The popular television program VOICES ... recently announced that it will be devoting an entire short segment to the subject ... people around the globe on a daily basis, but recent advancements in medical science ...
(Date:8/28/2015)... ... 2015 , ... Approximately 2,000 United Methodists are expected to ... children, a thank you to the many creative and generous ways in which ... Methodist initiative to end malaria deaths. , The Columbus Zoo and Aquarium event, ...
(Date:8/28/2015)... , ... August 28, 2015 ... ... for Medical Devices:, Understanding the FDA’s Position and Best Practices for Compliance, ... http://www.fdanews.com/cybersecuritymd , This workshop, chaired by internationally renowned expert Fubin Wu, ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5
... PA, 10 June, 2010 - Sex "addiction" is a ... the publicity associated with Tiger Woods. Persons with ... inhibit behaviors once they become maladaptive, despite adverse consequences ... is a brain region involved in decision-making and behavioral ...
... variants that are associated with blood levels of vitamin D ... The report from the SUNLIGHT consortium involving investigators from ... and is receiving early online release. ... for vitamin D deficiency," says Thomas Wang, MD, of the ...
... Oncology (ASTRO) has been named to the 2010 Associations ... its public awareness campaign to help cancer patients and ... ASTRO conducted a national survey to gauge what the ... public knew very little about this form of cancer ...
... coffee may help prevent diabetes and that caffeine may ... findings, among the first animal studies to demonstrate this ... Agricultural and Food Chemistry . Fumihiko Horio and ... coffee drinking may reduce the risk of type 2 ...
... taken by doctors committed to practicing medicine ethically. What happens ... cross the line and kill? When Doctors Kill covers ... reaching into the 21st century. History is replete with "good ... Joshua Perper and Dr. Stephen Cina, with a combined 60 ...
... performance of a complex motor-learning task such as "Guitar ... that will be presented Wednesday, June 9, 2010, in ... meeting of the Associated Professional Sleep Societies LLC. ... "Guitar Hero III" was greater after a night of ...
Cached Medicine News:Health News:Frontal cortex dysfunction may contribute to compulsive sexual behavior 2Health News:Genome-wide study identifies factors that may affect vitamin D levels 2Health News:ASTRO patient education program recognized by AAA Awards 2Health News:When doctors kill 2Health News:Sleep may help you become a 'Guitar Hero' 2
Provides exceptional resolution and fundus scanning capability. Excellent for small pupil diagnosis and treatment....
... 20D diagnostic/laser lens is perfectly corrected ... coma delivering the best retinal ... on the market. Its advanced double ... magnification and perfect image clarity across ...
The 15D provides high magnification along with an optimized working distance from the cornea. With its 4.11x magnification it is also well suited for disc and macular observation....
... The NIDEK MK-2000 ... performance in a wide ... MK-2000 utilizes single-use, ultra-sharp ... Blades are supplied sterile ...
Medicine Products: